Associate Professor Richard Benninger and his lab recently published a research article in Nature Communications “Contrast-enhanced ultrasound measurement of pancreatic blood flow dynamics predicts type 1 diabetes progression in preclinical models”. Non-invasive techniques to assess the progression of type 1 diabetes prior to clinical onset are needed, both for disease diagnosis and for monitoring the efficacy of therapeutic reversal. The Benninger lab applied a contrast-enhanced ultrasound measurement of mouse pancreatic blood flow to detect changes in the islet microvasculature that undergoes rearrangements during diabetes. These measurements predicted both rapid disease progression as well as the success of therapeutic interventions to reverse disease progression. This study is particularly significant as both the widespread deloyment of ultrasound modalities and the clinical approval of ultrasound contrast agents will facilitate clinical translation for monitoring disease progression in populations at risk for type1 diabetes. This study was primarily supported by funding from the JDRF and NIH, and lead author Josh St Clair was funded by the “Cardiovascular Imaging and Biomechanics” T32 training program and an F32 NRSA postdoctoral fellowship.